| [1] |
Ikegami T,Shirabe K,Soejima Y, et al. Feasibility of ABO-incompatible living donor liver transplantation in the rituximab era[J]. Liver Transpl, 2010, 16(11): 1332-1333.
|
| [2] |
Puttarajappa C,Shapiro R,Tan HP. Antibody-mediated rejection in kidney transplantation: a review[J]. J Transplant, 2012: 193724.
|
| [3] |
Hübscher SG. Antibody-mediated rejection in the liver allograft[J]. Curr Opin Organ Transplant, 2012, 17(3): 280-286.
|
| [4] |
Tanabe M,Kawachi S,Obara H, et al. Current progress in ABO-incompatible liver transplantation[J]. Eur J Clin Invest, 2010, 40(10): 943-949.
|
| [5] |
Tanabe M,Shimazu M,Wakabayashi G, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation[J]. Transplantation, 2002, 73(12): 1959-1961.
|
| [6] |
Shin M,Song SH,Kim JM, et al. Effectiveness of intraportal prostaglandin E1 administration after liver transplantation[J]. Transplant Proc, 2012, 44(2): 500-504.
|
| [7] |
Monden M. Liver transplantation in Japan-Registry by the Japanese Liver Transplantation Society[J]. Jpn J Transplant, 2004, 39(6): 634-642.
|
| [8] |
Egawa H,Teramukai S,Haga H, et al. Present status of ABO-incompatible living donor liver transplantation in Japan[J]. Hepatology, 2008, 47(1): 143-152.
|
| [9] |
Kobayashi S,Nagano H,Marubashi S, et al. Successful adult ABO incompatible living donor liver transplantation: experience with double infusion through the hepatic artery and portal vein[J]. Hepatogastroenterology, 2011, 58(106): 503-507.
|
| [10] |
Iwasaki K,Miwa Y,Haneda M, et al. AMP-activated protein kinase as a promoting factor, but complement and thrombin as limiting factors for acquisition of cytoprotection: implications for induction of accommodation[J]. Transpl Int, 2013, 26(11): 1138-1148.
|
| [11] |
Egawa H,Teramukai S,Haga H, et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study[J]. Am J Transplant, 2014, 14(1): 102-114.
|
| [12] |
Kim JM,Kwon CH,Joh JW, et al. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor[J]. J Hepatol, 2013, 59(6): 1215-1222.
|
| [13] |
Hashimoto T,Kondo S,Suzuki T, et al. Strategy for ABO-incompatible living-related liver transplantation[J]. Transplant Proc, 2000, 32(7): 2104-2106.
|
| [14] |
Goralczyk AD,Obed A,Schnitzbauer A, et al. Adult living donor liver transplantation with ABO-incompatible grafts: a German single center experience[J]. J Transplant, 2009: 759581.
|
| [15] |
Raut V,Mori A,Kaido T, et al. Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab[J]. Transplantation, 2012, 93(1): 99-105.
|
| [16] |
Jeng LB,Lee CC,Chiang HC, et al. Indication for splenectomy in the era of living-donor liver transplantation[J]. Transplant Proc, 2008, 40(8): 2531-2533.
|
| [17] |
Mor E,Skerrett D,Manzarbeitia C, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients[J]. Transplantation, 1995, 59(7): 986-990.
|
| [18] |
Hartono C,Kim J,McDermott J, et al. High-dose intravenous immunoglobulin (IVIG) adjuvant therapy for cell-mediated pancreas transplant rejection[J]. Transplantation, 2013, 96(5): e43-e44.
|
| [19] |
Ikegami T,Taketomi A,Soejima Y, et al. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation[J]. Transplantation, 2009, 88(3): 303-307.
|